Colchicine for coronary disease
Program Access
Listen And Gain Credits
Program Description

Inflammation is known to play an important role in the pathogenesis of atherosclerosis. Colchicine, an anti-inflammatory drug, has now been tested in several large trials of patients with coronary artery disease. While these trials have shown overall benefit on CV outcomes, there has been a trend towards increased non-CV death with colchicine. This podcast will explore the potential benefits of colchicine in CAD vs. the potential risks, and discuss whether colchicine should become a guideline-endorsed therapy for patients with CAD.

Learning Objectives

  • Review the role of inflammation in the pathogenesis of atherosclerosis.
  • Summarize the results and safety from cardiovascular inflammation outcomes trials.
  • Explore practice and guideline implications from cardiovascular inflammation outcomes trials.


This 1-credit-per-hour Self-Learning program has been certified by the College of Family Physicians of Canada and the Ontario Chapter for up to 0.5 Mainpro+® credits. 


This program was developed by the Canadian Collaborative Research Network, a not-for-profit physician organization.  No outside funding support was received for this program. 

Back To Programs


Being a part of CCRN has benefits